UNAIDS to slash workforce as funding by United States and other donors disappears
The UN agency that fights HIV plans to slash its workforce by more than half and move many posts to cheaper locations as a result of drastic funding cuts from long-time donors in the United States, Asia and Europe, the agency and staffers have said.
UNAIDS said "the overall global AIDS response is facing a severe shock and many of the gains made in the past few decades are at risk of being reversed."
It said the restructuring follows an independent panel's recommendations calling for "downsizing" its secretariat in Geneva while continuing to "prioritise the most essential functions."
It said it would maintain its presence in 36 countries.
The headquarters of the World Health Organization and UNAIDS in Geneva, 8 April, 2019
AP Photo
Drastic US cuts in assistance under the Trump administration, part of wider cuts for global health, strike perhaps the biggest blow ever to the world's efforts to fight HIV.
UNAIDS had previously warned that unless support to its HIV efforts are restored soon, more than six million people could die in the next four years and an additional 2,000 people per day could become infected with the virus that causes AIDS.
Employees were told at an internal town hall on Tuesday that staff will be reduced to around 280-300 from about 600 currently, participants said.
UNAIDS officials were considering plans to move many posts to lower-cost locations where it already has offices: in Bonn, Germany; Nairobi, Kenya; or Johannesburg, South Africa, the country with the world's highest number of AIDS cases, agency spokesperson Charlotte Sector said.
Related
UNAIDS chief urges Donald Trump to make an 'amazing deal' to end HIV
'People are going to die': HIV infections could surge if US support is dropped, UNAIDS chief says
UN agencies slash jobs, warn of impact to services amid US funding cuts, officials say
UNAIDS was created in 1996, largely to address shortcomings in global HIV policy by another UN health agency, the World Health Organisation (WHO), which continues to partially fund it.
The United States, under the second Trump administration, has sharply reduced or paused international funding and support for many UN-related agencies.
In an in February in response to the US cuts, UNAIDS Executive Director Winnie Byanyima said HIV infections could jump more than six times by 2029 if US support of the biggest AIDS programme is dropped.
She warned that more resistant strains of the disease could emerge.
Byanyima acknowledged some valid criticism regarding how HIV aid has been delivered and called it "an opportunity to rethink and develop more efficient ways of delivering life-saving support."
Winnie Byanyima, Executive Director of UNAIDS, speaks during a press conference in Geneva, 24 March, 2025
AP Photo
According to its website,
support from the United States
contributed more than 40% of the UNAIDS core program and non-core activities that totalled about $214 million (€188 million) in 2023, the most recent year listed.
Other top contributors included the Netherlands, Sweden, Switzerland and the UK.
ADVERTISEMENT
In April, the World Food Programme (WFP) and other UN agencies said they would have to slash jobs because of funding cuts, mainly from the United States, warning the reductions would severely affect aid programmes worldwide.
Other bodies like UNICEF, the UN children's agency, and OCHA, the humanitarian agency, also announced cuts that would impact around 20% of staff and overall budgets.
The cuts to the UN agencies underscore the impact of President Donald Trump's decision to pull the US back from its position as the world's single largest aid donor.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Euronews
18 hours ago
- Euronews
Cats develop dementia similarly to humans, study finds
Cats develop dementia similarly to humans, according to new research that scientists say could help them explore new treatments for the disease. Researchers from the University of Edinburgh carried out post-mortem examinations on the brains of 25 cats, all of which had exhibited symptoms of feline dementia. Symptoms can include confusion, disrupted sleep cycles, more frequent vocalisation, and missing the litter box, according to the study, which was published in the European Journal of Neuroscience. Using powerful microscopy images, the researchers found an accumulation of amyloid-beta plaques in the cats' brains. These plaques are a toxic protein that affect the brain's ability to communicate messages and remember things, and they are characteristic of Alzheimer's disease. "Our findings highlight the striking similarities between feline dementia and Alzheimer's disease in people," said Robert McGeachan, the study's lead author and a lecturer at the University of Edinburgh's veterinary school. "Because cats naturally develop these brain changes, they may also offer a more accurate model of the disease than traditional laboratory animals, ultimately benefiting both species and their caregivers,' McGeachan added. Typically, scientists study dementia with genetically modified rodents, which don't naturally develop the syndrome. Feline dementia, however, is the "perfect natural model for Alzheimer's," said Danièlle Gunn-Moore, a feline medicine professor at the school. The development could help lead to a more advanced understanding of how the disease progresses, and the creation of new treatments in the future, the researchers said. "Feline dementia is so distressing for the cat and for its person," Gunn-Moore said. "It is by undertaking studies like this that we will understand how best to treat them". Alzheimer's is the most common form of dementia, according to the World Health Organization (WHO), contributing to an estimated 60 per cent to 70 per cent of cases. While there is currently no known cure, medications can help some people manage symptoms.
Euronews
19 hours ago
- Euronews
Extreme heat is also a public health emergency, experts warn
Extreme weather events are not only a climate crisis but also a public health one, straining health systems, economies and the lives of those most at risk, the Pan-European Commission on Climate and Health (PECCH) warns in an open letter to the World Health Organization. 'This is no longer a distant threat or seasonal nuisance. It is a public health emergency unfolding in real time," states the letter, sent on Wednesday. The commission is an independent group bringing together climate and health experts from across Europe, convened by WHO Regional Director Dr Hans Kluge. It was established in June 2025 and will prepare recommendations for accelerated health and climate action to be presented at the World Health Assembly in May 2026. The European region is experiencing record-breaking heatwaves, that are becoming more frequent, more intense and deadlier, and which they warn are silent killers. During periods of very high temperature, the human body may struggle to regulate itself, leading to heat stress, heat exhaustion, heatstroke, and complications from pre-existing medical conditions, sometimes resulting in premature death. Of all weather- and climate-related extreme events in Europe, heat causes the largest number of deaths. Heat-related mortality has risen by 30% in the past two decades, with more than 100,000 deaths recorded across 35 European countries in 2022 and 2023 combined, and is expected to continue to rise. Population groups at risk include older people, people with disabilities, pregnant women, children, outdoor workers, and those living in inadequately prepared housing. The health effects of climate change can also be seen in the rise of vector-borne diseases — those transmitted by mosquitoes — such as dengue, West Nile virus, and chikungunya Last year, there were 1,436 cases of West Nile virus and 304 dengue infections acquired in Europe, up from 201 the previous two years combined, according to the European Centre for Disease Prevention and Control (ECDC). Critical situation for healthcare systems The letter warns that the situation is exposing gaps in response systems and placing severe strain on health services. 'Heat-health action plans save lives by triggering early action, protecting the most vulnerable and easing pressure on hospitals. Accelerating the adoption of these plans must be a priority – not in a few years, but now," the coalition said. In Portugal, daily hospital admissions increased by 19% during heatwave days between 2000 and 2018, while in France, in 2022, emergency department visits doubled and consultations with physicians tripled during heatwaves for heat-related conditions. The PECCH also stresses the need to invest in prevention and calls for 'new measures of progress that put health, well-being, equity and sustainability at their core'. 'The climate crisis is a health crisis, and climate action is therefore health action," they add in the letter. Measures such as cutting emissions and expanding green spaces, they say, directly benefit both the environment and public health. For example, increasing urban greenery by 30% could cut heat-related deaths by up to 40%.
LeMonde
2 days ago
- LeMonde
Trump keeps up the pressure on pharmaceutical companies amid tariff uncertainty
In recent months, pressure on pharmaceutical manufacturers has continued to mount across the Atlantic due to tariff uncertainty, demands for lower drug prices and disruptions caused by shifting policies or staff changes within US health agencies. Although laboratories remain exempt from tariffs for now, they have tried to present a relatively calm front. Still, Donald Trump's repeated attacks on the industry do little to ease concerns. The US president once again caused a stir on August 5. Speaking on CNBC, Trump reiterated his threat to raise tariffs on health products imported into the US to dramatic levels, aiming to force drug manufacturers to bring their production back onto American soil. "We'll be putting an initially small tariff on pharmaceuticals, but in one year, one-and-a-half years maximum, it's going to go to 150%, then it's going to go to 250%, because we want pharmaceuticals made in our country," he stated. Manufacturers − under pressure for months from the US administration to comply with Trump's demands − have already announced a series of major investments in the US since February. American laboratories such as Eli Lilly, Johnson & Johnson, AbbVie, Bristol Myers Squibb, Gilead and Regeneron; Swiss companies Roche and Novartis; Japan's Takeda; France's Sanofi; and the United Kingdom's AstraZeneca have together pledged nearly $320 billion over the next five years to strengthen and expand their industrial presence in the US.
